Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 29, 2016

View Archived Issues

Zinc-13407541 partially reverses hypophosphatemic effects of excess FGF-23 in vivo

Janssen initiates phase IIb study of simeprevir, odalasvir and AL-335 for HCV

IL-31 levels are upregulated in dermatomyositis

PRMT5 inhibitors could represent new therapeutic approach in treatment of psoriatic diseases

Hetero Research Foundation patents antiviral agents

Blueprint Medicines reports data from ongoing phase I trial of BLU-554 in HCC

FDA gives fast track designation to Epizyme's tazemetostat

Sichuan Haisco Pharmaceutical discloses M3 receptor antagonist and/or beta2-adrenoreceptor agonists

Bristol-Myers Squibb describes bromodomain inhibitors

FDA accepts sBLA for Keytruda in patients with MSI-H cancer

Kancera develops HDAC inhibitors

European Commission approves Glyxambi for type 2 diabetes

Phase II trial of cavosonstat in cystic fibrosis does not meet primary endpoint

EMA grants full aproval to vismodegib

Oxford BioMedica establishes strategic alliance with Orchard Therapeutics

Mutations in FAM105B gene may be involved in autoinflammatory diseases

GTx's enobosarm achieves primary efficacy endpoint in phase II trial

Inisync available in Japan

Idera and Vivelix sign license and collaboration agreement for IMO-9200

MonoSol files NDA with FDA for Tadalafil PharmFilm in the treatment of erectile dysfunction

Cyfip2 is a genome-wide significant genetic factor for binge eating

Galapagos initiates phase I study of GLPG-2737 in cystic fibrosis

Relypsa's patiromer gains FDA approval of sNDA, black box warning removed from label

Recro Pharma discloses positive results from phase III trial of i.v. meloxicam

VB-037 shows promise in EAE model

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 16, 2026.
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...